Severe Sepsis Biomarkers: A Contemporary Review for Critical Care Practice

Dr Neeraj Manikath , claude.ai

Abstract

Background: Sepsis remains a leading cause of morbidity and mortality in critically ill patients, with early recognition and appropriate management being crucial for improved outcomes. Biomarkers play an increasingly important role in sepsis diagnosis, prognosis, and therapeutic guidance.

Objective: To provide a comprehensive review of established and emerging biomarkers in severe sepsis, with emphasis on clinical applications, limitations, and future directions.

Methods: Narrative review of current literature focusing on procalcitonin, lactate clearance, and emerging biomarkers including presepsin and suPAR, with critical evaluation of their clinical utility.

Results: Procalcitonin demonstrates robust evidence for antibiotic stewardship, while lactate clearance remains a cornerstone of resuscitation monitoring. Emerging biomarkers show promise but require further validation.

Conclusions: A multimodal biomarker approach, integrated with clinical assessment, offers the most comprehensive strategy for sepsis management in the critical care setting.

Keywords: Sepsis, biomarkers, procalcitonin, lactate, presepsin, suPAR, critical care

Introduction

Sepsis, defined as life-threatening organ dysfunction caused by a dysregulated host response to infection, affects over 48 million people globally each year, with mortality rates ranging from 15-30% in severe cases¹. The heterogeneous nature of sepsis, combined with its rapid progression, necessitates precise diagnostic and prognostic tools to guide therapeutic interventions. Biomarkers have emerged as invaluable adjuncts to clinical assessment, offering objective measures for diagnosis, risk stratification, treatment monitoring, and prognostication.

The evolution of sepsis definitions, from SIRS-based criteria to the current Sepsis-3 definitions emphasizing organ dysfunction, has paralleled advances in biomarker research². This review examines the current evidence and clinical applications of established biomarkers, with particular focus on procalcitonin and lactate clearance, while exploring the potential of emerging markers including presepsin and soluble urokinase-type plasminogen activator receptor (suPAR).

Procalcitonin: The Antibiotic Stewardship Game-Changer

Pathophysiology and Diagnostic Utility

Procalcitonin (PCT), the 116-amino acid precursor of calcitonin, represents one of the most extensively studied sepsis biomarkers. Under physiological conditions, PCT is undetectable in healthy individuals (<0.05 ng/mL). During bacterial infections, however, ubiquitous PCT production occurs in response to bacterial toxins and inflammatory mediators, particularly TNF-α, IL-1β, and IL-6³.

Clinical Pearl: PCT levels >0.5 ng/mL suggest bacterial infection with high specificity, while levels >2.0 ng/mL are associated with severe bacterial infection or sepsis⁴.

Evidence for Antibiotic De-escalation

The most compelling evidence for PCT lies in its role for antibiotic stewardship. The ProHOSP study demonstrated that PCT-guided therapy reduced antibiotic exposure by 2.4 days without compromising clinical outcomes⁵. Subsequently, multiple randomized controlled trials have consistently shown:

Reduced antibiotic duration: 2-3 days shorter courses without increased mortality
Decreased antibiotic resistance: Lower selective pressure on hospital flora
Cost-effectiveness: Significant reduction in antibiotic-related costs

The STOP-IT trial, involving 1,575 ICU patients, showed that PCT-guided discontinuation of antibiotics reduced treatment duration from 7.5 to 5.7 days (p<0.001) with no difference in mortality⁶.

PCT-Guided Protocols: The "50% Rule"

Hack for Clinical Practice: Implement the "50% rule" for antibiotic discontinuation:

Stop antibiotics when PCT decreases by ≥50% from peak value AND
PCT level <0.5 ng/mL OR
After 5-7 days regardless of PCT level (safety net)

Limitations and Pitfalls

Oyster Alert: PCT has several important limitations:

Elevated in non-infectious conditions (cardiogenic shock, severe burns, major surgery)
May remain elevated in patients with renal dysfunction
Less reliable in immunocompromised patients
Can be falsely low in early sepsis or localized infections

Lactate Clearance: The Metabolic Mirror of Sepsis

Physiological Basis

Lactate elevation in sepsis results from multiple mechanisms:

Tissue hypoxia: Classical oxygen debt theory
Metabolic dysfunction: Mitochondrial dysfunction and cytopathic hypoxia
Accelerated aerobic glycolysis: Stress response and catecholamine effect⁷

The 6-Hour Lactate Clearance Paradigm

Lactate clearance, defined as the percentage decrease in lactate levels over time, has emerged as a superior prognostic marker compared to absolute lactate values. The landmark study by Nguyen et al. established that >10% decrease in lactate at 6 hours was associated with improved survival⁸.

Clinical Pearl: Lactate clearance >10% at 6 hours is associated with:

Reduced ICU mortality (17% vs 60%, p<0.001)
Shorter ICU length of stay
Improved organ dysfunction scores

Implementation Strategy

The CLEAR Protocol:

Check initial lactate within 1 hour of sepsis recognition
Lactate recheck at 2-6 hours
Evaluate clearance: [(Initial lactate - Follow-up lactate) / Initial lactate] × 100
Adjust resuscitation if clearance <10%
Repeat every 6 hours until normalized

Lactate-Guided vs. ScvO₂-Guided Therapy

The ProCESS, ARISE, and ProMISe trials collectively demonstrated that lactate clearance is non-inferior to ScvO₂ monitoring for resuscitation endpoints, with greater feasibility and cost-effectiveness⁹.

The Lactate Controversy: To Measure or Not in Non-Shock Patients?

The Argument Against Routine Measurement

Critics argue that routine lactate measurement in hemodynamically stable patients may lead to:

Overtreatment: Unnecessary fluid resuscitation in patients without tissue hypoxia
False alarms: Lactate elevation from non-hypoxic causes (medications, liver dysfunction)
Resource utilization: Increased costs without proven benefit

The Case for Routine Measurement

Proponents emphasize:

Occult hypoperfusion: Up to 25% of normotensive patients have elevated lactate¹⁰
Prognostic value: Even mild lactate elevation (2-4 mmol/L) predicts mortality
Treatment modification: Early recognition allows for timely intervention

Current Consensus: The Surviving Sepsis Campaign 2021 guidelines recommend lactate measurement in all patients with suspected sepsis, regardless of blood pressure, as part of initial assessment¹¹.

Emerging Biomarkers: The Next Generation

Presepsin (sCD14-ST): The Monocyte Activation Marker

Presepsin, a soluble fragment of CD14, is released when monocytes are activated by bacterial lipopolysaccharide. Several studies have demonstrated its potential advantages:

Diagnostic Performance

Sensitivity: 85-90% for sepsis diagnosis
Specificity: Superior to PCT in distinguishing sepsis from SIRS
Early detection: Rises within 2 hours of onset¹²

Clinical Pearl: Presepsin levels >400 pg/mL suggest sepsis with high specificity, while levels >800 pg/mL indicate severe sepsis.

Advantages Over Traditional Markers

Less affected by renal function compared to PCT
Minimal elevation in viral infections
Rapid kinetics allow real-time monitoring

suPAR: The Immune System Integrator

Soluble urokinase-type plasminogen activator receptor (suPAR) reflects immune system activation and has emerged as a promising prognostic biomarker.

Clinical Applications

Mortality prediction: Levels >12 ng/mL associated with increased 30-day mortality¹³
ICU triage: Helps identify patients requiring intensive monitoring
Long-term prognosis: Predicts 1-year mortality in sepsis survivors

Hack for Risk Stratification:

suPAR <6 ng/mL: Low risk
suPAR 6-12 ng/mL: Intermediate risk
suPAR >12 ng/mL: High risk (consider aggressive intervention)

The Multimodal Biomarker Approach

Integrative Strategy

Modern sepsis management increasingly relies on combining multiple biomarkers:

Diagnostic Phase: PCT + Presepsin for infection confirmation
Resuscitation Phase: Lactate clearance for hemodynamic monitoring
Prognostic Phase: suPAR for risk stratification
De-escalation Phase: PCT for antibiotic stewardship

The SEPSIS Score Integration

Proposed Clinical Algorithm:

Initial Assessment:
- PCT >0.5 ng/mL + Presepsin >400 pg/mL = High probability bacterial sepsis
- Initiate antibiotics + measure lactate

Resuscitation Monitoring (0-6 hours):
- Target lactate clearance >10% at 6 hours
- If <10% clearance, reassess hemodynamics and consider escalation

Antibiotic De-escalation (48-72 hours):
- PCT decreased >50% from peak: Consider stopping antibiotics
- PCT <0.5 ng/mL: Strong indication for discontinuation

Prognostic Assessment:
- suPAR >12 ng/mL: High-risk patient, consider intensive monitoring

Clinical Pearls and Practical Hacks

The "Rule of Tens" for Lactate

1.0 mmol/L: Normal upper limit
2.0 mmol/L: Consider sepsis workup
4.0 mmol/L: Severe hypoperfusion, aggressive resuscitation
10.0 mmol/L: Consider ECMO/advanced support
10% clearance: Target for 6-hour improvement

PCT Interpretation Pitfalls

Remember the "5 C's":

CKD: Levels may be elevated due to reduced clearance
Cardiogenic shock: Can cause false elevation
Cirrhosis: May have delayed PCT response
Cancer: Baseline elevation possible
Corticosteroids: May blunt PCT response

Presepsin Practical Points

More stable than PCT at room temperature
Less affected by timing of collection
Particularly useful in post-operative patients
Consider in patients with suspected healthcare-associated infections

Future Directions and Research Priorities

Personalized Medicine Applications

Pharmacogenomics: Tailoring antibiotic therapy based on genetic markers
Host response profiling: Identifying endotypes of sepsis for targeted therapy
Machine learning integration: Combining biomarkers with clinical data for predictive modeling

Point-of-Care Testing

Development of rapid, bedside biomarker panels including:

Multi-analyte platforms combining PCT, lactate, and presepsin
Microfluidic devices for real-time monitoring
Integration with electronic health records for automated alerts

Novel Biomarkers Under Investigation

MicroRNAs: miR-15a, miR-16, miR-122 showing promise for sepsis diagnosis
Metabolomics panels: Comprehensive metabolic profiling for personalized therapy
Cell-free DNA: Pathogen identification and antimicrobial resistance prediction

Limitations and Considerations

General Limitations of Sepsis Biomarkers

Lack of pathogen specificity: Cannot distinguish bacterial from viral infections with perfect accuracy
Kinetic variability: Different time courses of elevation and clearance
Cost considerations: Economic impact of routine biomarker monitoring
Training requirements: Need for education on proper interpretation

Implementation Challenges

Standardization: Variability in assay platforms and reference ranges
Integration: Incorporating biomarker results into clinical decision-making
Resistance to change: Overcoming traditional practice patterns

Recommendations for Clinical Practice

Level A Recommendations (Strong Evidence)

Use PCT for antibiotic de-escalation in patients with suspected bacterial infections
Monitor lactate clearance as a resuscitation endpoint in septic patients
Measure initial lactate in all patients with suspected sepsis

Level B Recommendations (Moderate Evidence)

Consider presepsin as an adjunct to PCT for sepsis diagnosis
Use suPAR for prognostic assessment in severe sepsis
Implement multimodal biomarker strategies for comprehensive sepsis management

Level C Recommendations (Expert Opinion)

Develop institutional protocols for biomarker-guided therapy
Provide education on biomarker interpretation for all critical care staff
Consider cost-effectiveness when implementing biomarker programs

Conclusion

Sepsis biomarkers have evolved from simple diagnostic aids to sophisticated tools for personalized sepsis management. Procalcitonin has established itself as the gold standard for antibiotic stewardship, while lactate clearance remains fundamental for resuscitation monitoring. Emerging biomarkers like presepsin and suPAR offer additional dimensions for diagnosis and prognosis.

The future of sepsis biomarkers lies not in single "magic bullets" but in integrated, multimodal approaches that combine multiple markers with clinical assessment and advanced analytics. As we move toward precision medicine in critical care, biomarkers will play increasingly important roles in delivering individualized, evidence-based sepsis care.

The key to successful implementation lies in understanding each biomarker's strengths and limitations, developing institutional protocols, and maintaining a patient-centered approach that uses biomarkers to enhance, not replace, clinical judgment.

References

Singer M, Deutschman CS, Seymour CW, et al. The Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315(8):801-810.
Rudd KE, Johnson SC, Agesa KM, et al. Global, regional, and national sepsis incidence and mortality, 1990-2017: analysis for the Global Burden of Disease Study. Lancet. 2020;395(10219):200-211.
Schuetz P, Chiappa V, Briel M, Greenwald JL. Procalcitonin algorithms for antibiotic therapy decisions: a systematic review of randomized controlled trials and recommendations for clinical algorithms. Arch Intern Med. 2011;171(15):1322-1331.
Wacker C, Prkno A, Brunkhorst FM, Schlattmann P. Procalcitonin as a diagnostic marker for sepsis: a systematic review and meta-analysis. Lancet Infect Dis. 2013;13(5):426-435.
Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA. 2009;302(10):1059-1066.
de Jong E, van Oers JA, Beishuizen A, et al. Efficacy and safety of procalcitonin guidance in reducing the duration of antibiotic treatment in critically ill patients: a randomised, controlled, open-label trial. Lancet Infect Dis. 2016;16(7):819-827.
Garcia-Alvarez M, Marik P, Bellomo R. Sepsis-associated hyperlactatemia. Crit Care. 2014;18(5):503.
Nguyen HB, Rivers EP, Knoblich BP, et al. Early lactate clearance is associated with improved outcome in severe sepsis and septic shock. Crit Care Med. 2004;32(8):1637-1642.
ProCESS Investigators, Yealy DM, Kellum JA, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370(18):1683-1693.
Mikkelsen ME, Miltiades AN, Gaieski DF, et al. Serum lactate is associated with mortality in severe sepsis independent of organ failure and shock. Crit Care Med. 2009;37(5):1670-1677.
Evans L, Rhodes A, Alhazzani W, et al. Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021. Crit Care Med. 2021;49(11):e1063-e1143.
Ulla M, Pizzolato E, Lucchiari M, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicentre prospective study. Crit Care. 2013;17(4):R168.
Giamarellos-Bourboulis EJ, Norrby-Teglund M, Mylona V, et al. Risk assessment in sepsis: a new prognostication rule by APACHE II score and serum soluble urokinase plasminogen activator receptor. Crit Care. 2012;16(4):R149.

Saturday, August 16, 2025